Detected ·
EXCIVA GmbH
——
EXCIVA GmbH extended its Series B financing round to €53 million, dosed the first patient in its Phase 2/3 trial of Deraphan for agitation in Alzheimer's disease, and appointed Nadine Knowles as Chief Operating Officer.
- Website
- www.exciva.com
- linkedin.com/company/exciva-gmbh
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-01 16:08:05 UTC
- Signal ID
- 0aed84c4-8451-47b0-91b2-14e0c2603cf4
As the API returns it
{
"id": "0aed84c4-8451-47b0-91b2-14e0c2603cf4",
"created_at": "2026-05-01T16:08:05.271079Z",
"company_name": "EXCIVA GmbH",
"company_website_url": "www.exciva.com",
"company_linkedin_url": "https://www.linkedin.com/company/exciva-gmbh",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*EXCIVA GmbH extended its Series B financing round to €53 million, dosed the first patient in its Phase 2/3 trial of Deraphan for agitation in Alzheimer's disease, and appointed Nadine Knowles as Chief Operating Officer.*"
}